CHU de Québec-Université Laval Research Centre
The logical choice for oncology clinical trials in the Quebec City region and all of eastern Quebec
Oncology is an area where the CHU de Québec-Université Laval stands out, especially in terms of early-stage clinical research. Many projects in radiation oncology, pediatric oncology, urology, breast cancer, dermatology, and other tumour sites are launched every year, in addition to the other therapeutic areas such as infectious diseases, endocrinology, neurology and ophthalmology.
Having a broad scope of activities due to its geographical location and many areas of expertise, the CHU de Québec-Université Laval is a key player in privately funded clinical research. The institution is known for its ability to recruit patients from the Quebec City region and all of eastern Quebec. The CHU de Québec also stands out for its expertise in analyzing large volumes of data on patient metabolism and microbiota thanks to its special access to the experts at Université Laval’s Big Data Research Centre (BDRC).
Areas of expertise
Endocrinology and nephrology, infectious and immune diseases, neuroscience, oncology, reproduction, mother and child health, population health and optimal health practices and medical physics.
Preclinical studies and phase l to lV clinical studies sponsored by pharmaceutical companies, supported by academic funding or by cooperative groups, investigator-initiated or not.
A clinical and evaluative research platform to support physician-researchers and their teams with respect to training, ethics, methodology and biostatistics.
Access to several technological platforms
- Tissue engineering
- Analytical and medicinal chemistry
- Imaging and cytometry
- Animal facility
- Dynamic hematology-oncology team with a focus on phase I trials
- Clean room cell culture service
- Mère-Enfant Soleil pediatric centre
With the opening of the New Hospital Complex (NCH) slated for 2021, the community of researchers will have access to an innovative, cutting-edge research environment with a cyclotron and a new Integrated Cancer Centre (CIC), while optimizing even further the cohesion between the different specialties.
Investigators specializing in phase I trials
Dr. Maxime Chénard-Poirier – oncology
Dr. Vincent Castonguay – oncology
Dr. Bruno Michon – pediatric oncology
Dr. Louis Lacombe – oncology
Dr. Marc Dionne – infectious and immune diseases
Dr. Marie-Louise Vachon – infectious and immune diseases
Dr. Valérie Larouche – pediatric oncology
Dr. Brigitte Poirier – oncology
Dr. Jean-François Larouche – oncology
Dr. Louis Verret – neuroscience
Dr. Alexis Turgeon – population health and optimal health practices
Dr. André Blais – oncology
Dr. François Boucher – infectious and immune diseases
Dr. Jean-Mathieu Beauregard – oncology
Dr. Claudia Gagnon – endocrinology and nephrology
Dr. Isabelle Thibault – oncology
To contact them, please refer to the researcher directory.
Research Directorate – Clinical Research (PRCE)
CHU de Québec-Université Laval (CHUL) Research Centre
2705 boul. Laurier, Québec G1V 4G2
418-525-4444 ext. 48545